Heyholder
‹ Activism Filings

HWAIL PHARM. CO., LTD Q3 revenue KRW 24.0 billion, operating loss of KRW 0.8 billion after profit a year earlier

HWAIL PHARM. CO., LTD· Periodic Report

AI summary · Not investment advice

Hwail Pharmaceuticals sold KRW 24.0 billion in the third quarter and lost KRW 0.8 billion from its main business, down from a profit a year earlier.

Operating profit · 3 months

KRW -780.7 million

Key facts

Revenue (3 months)
KRW 24.0 billion
Net income (3 months)
KRW -1.9 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 24.3 billion
Revenue (year to date)
KRW 71.9 billion
Operating profit (prior-year 3 months)
KRW 165.2 million
Operating profit (year to date)
KRW -2.3 billion
Net income (prior-year 3 months)
KRW 388.4 million
Net income (year to date)
KRW 3.0 billion

Commentary

AI commentary · Not investment advice

What happened

Hwail Pharm reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 24.0 billion. That is 1.3% lower than the same period a year earlier and 1.9% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 0.78 billion, a swing from a profit of KRW 0.17 billion a year earlier. Net income (final profit after taxes and all other items) for the 3 months was a loss of KRW 1.93 billion, a swing from a profit of KRW 0.39 billion a year earlier.

What changes for shareholders

For January 1 to September 30, cumulative sales were KRW 71.9 billion. Cumulative operating profit was a loss of KRW 2.26 billion. Cumulative net income was a profit of KRW 3.02 billion.

Comments

No comments yet

Comments from shareholders will appear here.